Repurposing an anti-diabetic drug into an anti-cancer drug: Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Pioglitazone (trade name: Actos), an anti-diabetic drug, increases the expression of tumor suppressors genes, such as  TIMP3, CCM3/KRIT1, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 28/August/2018, 12.09 am

A sere(ne)laxin-way to stay free of cardiac diseases: Serelaxin-based therapy for attenuating pathogenesis-associated with Myocardial infarction: Serelaxin, a recombinant Relaxin-2,  decreases IRF3 (Interferon regulatory transcription factor-3), GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up-regulation of its target gene, 27/August/2018, 11.25 pm
August 27, 2018
Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: PCGF2/Mel-18 increases the expression of tumor suppressors genes, such as  FBOX11, Sprouty1/2, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 28/August/2018, 12.17 am
August 27, 2018
Show all

From Significance of the study to Public health relevance

Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.


From therapeutic strategy to Research Findings:

(i) Therapeutic strategy: 

This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.

(ii) Research findings:  

Pioglitazone (Actos) has been shown to function as a tumor suppressor in a number of cancers. However, the mechanism of action remains largely unknown.

Figure 1. Mechanistic insight into how  Pioglitazone (Actos) functions as an anticancer/antimetastatic agent in mutant p53-expressing tumors.  Pioglitazone (Actos),  by activating tumor/metastasis suppressor genes, such as TIMP3, CCM3/KRIT1, p53, TAp63, TAp73, INK4a/ARF and others, in metastatic tumors, it may inhibit the progression of mutant-p53 expressing human cancers.

Figure 2. Pioglitazone (Actos) functions as an anti-tumor/metastatic agent through induction of tumor/metastatic suppressor genes, such as  TIMP3, CCM3/KRIT1,  p53, TAp63, TAp73, and INK4aThis study suggests that PCGF2/Mel-18 may function as an anti-cancer/metastasis agent by increasing the expression a number of tumor/metastasis suppressor genes.

Pioglitazone (Actos), by increasing the expression of its target gene, it may increase the expression of tumor/metastasis suppressors genes, such as TIMP3, CCM3/KRIT1, TA-p73, TAp63, p53, INK4a/ARF and others. Thereby, it may inhibit the migration and invasion of metastatic cancer cells expressing mutant-p53 (figure1).

 


Therapeutic opportunity:

Given the ability of Pioglitazone (Actos) to induce the expression of a number of tumor/metastasis suppressor genes, it may be used, either alone or in combination with other anticancer drugs, to inhibit the progression of p53-mutated invasive metastatic tumors. Taken together, this study suggests, for the first time, that oncologists may consider treating metastatic cancer patients with Pioglitazone (Actos), as it may stall the progression of advanced metastatic cancers. (figure 2).


Details of the research findings

Idea Proposed/Formulated by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $300#

Undisclosed mechanistic information: How Pioglitazone (Actos) increases the expression of tumor suppressor genes, such as TIMP3, CCM3/KRIT1, p53, TAp63, TAp73, INK4a/ARF and others,  in mutant p53 expressing cancer cells?

For purchase and payment details, you may reach us at admin@genomediscovery.org

#Research cooperation

[easy_payment currency=”USD”]


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Repurposing an anti-diabetic drug into an anti-cancer drug: Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Pioglitazone (trade name: Actos), an anti-diabetic drug, increases the expression of tumor suppressors genes, such as  TIMP3, CCM3/KRIT1, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 28/August/2018, 12.09 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.